BioCentury
ARTICLE | Company News

Albireo in elobixibat royalty deal with HealthCare Royalty

January 12, 2018 6:24 PM UTC

HealthCare Royalty Partners (Stamford, Conn.) entered into a deal with the Elobix AB subsidiary of Albireo Pharma Inc. (NASDAQ:ALBO). In exchange for royalties and milestones related to elobixibat and payable by the EA Pharma Co. Ltd. subsidiary of Eisai Co. Ltd. (Tokyo:4523), HealthCare Royalty will pay Elobix $45 million if the candidate is approved in Japan to treat chronic constipation, plus up to $15 million in sales milestones...